X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.fiercebiotech.com/biotech/vertex-scores-phase-3-gold-after-next-gen-cystic-fibrosis-treatment-goes-against-trikafta
https://www.fiercepharma.com/pharma/while-vertex-gears-next-generation-cf-treatment-trikafta-remains-formidable
https://www.fiercepharma.com/pharma/nices-trikafta-snub-could-portend-another-pricing-standoff-between-vertex-and-uk
https://www.pharmaceutical-technology.com/news/vertex-fda-cystic-fibrosis-2/
https://www.businesswire.com/news/home/20230426005815/en/Vertex-Announces-U.S.-FDA-Approval-for-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor-and-ivacaftor-in-Children-With-Cystic-Fibrosis-Ages-2-Through-5-With-Certain-Mutations
https://www.businesswire.com/news/home/20230426005815/en/Vertex-Announces-U.S.-FDA-Approval-for-TRIKAFTA%C2%AE-elexacaftortezacaftorivacaftor-and-ivacaftor-in-Children-With-Cystic-Fibrosis-Ages-2-Through-5-With-Certain-Mutations
https://www.biospace.com/article/releases/vertex-announces-health-canada-market-authorization-for-orkambi-and-174-lumacaftor-ivacaftor-in-children-with-cystic-fibrosis-ages-1-to-and-lt-2-years/
https://www.biospace.com/article/after-cystic-fibrosis-trial-failure-eloxx-shifts-focus-to-kidney-disease/
https://www.nasdaq.com/articles/vertex-vrtx-cf-drug-gets-fda-expanded-label-for-toddlers
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-ivacaftor-1655270244.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-aprepitant-azilsartan-bupivacaine-cladribine-elrombopag-fosnetupitant-fostamatinib-ivacaftor-and-sodium-thiosulfate-1655270821.pdf
https://www.expresspharma.in/lupin-gets-us-fda-nod-for-generic-drug/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216074
https://www.pharmatimes.com/news/european_commission_approves_cystic_fibrosis_treatment_for_six_to_11-year-olds_1386105
https://www.biospace.com/article/releases/vertex-s-supplement-to-a-new-drug-submission-for-kalydeco-and-174-ivacaftor-for-patients-with-cystic-fibrosis-between-the-ages-of-4-months-and-18-years-with-the-r117h-mutation-in-the-cftr-gene-accepted-for-priority-review-by-health-canada/?s=71
https://www.biospace.com/article/releases/vertex-announces-letter-of-intent-with-pan-canadian-pharmaceutical-alliance-for-public-reimbursement-of-cftr-modulators-extended-to-include-trikafta-and-174-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-/?s=100
http://www.pharmatimes.com/news/vertexs_kalydeco_scores_another_label_extension_in_eu_1356174
https://www.pharmiweb.com/press-release/2020-11-05/vertex-announces-european-commission-approval-for-kalydeco-ivacaftor-as-first-and-only-cftr-modulator-to-treat-eligible-infants-with-cystic-fibrosi
https://www.cff.org/News/News-Archive/2020/FDA-Approves-Kalydeco-for-Infants-as-Young-as-4-Months/#:~:text=The%20U.S.%20Food%20and%20Drug%20Administration%20(FDA)%20has%20approved%20the,months%20who%20have%20certain%20mutations.&text=Modulator%20treatmentthat%20provides%20more%20than,50%20percentreduction%20in%20pulmonary%20exacerbations.
https://seekingalpha.com/pr/18020197-fda-approves-kalydeco-ivacaftor-first-and-only-cftr-modulator-to-treat-eligible-infants-cf
https://www.businesswire.com/news/home/20200924005175/en/Vertex-to-Present-New-Data-at-European-and-North-American-Virtual-Cystic-Fibrosis-Conferences-Highlighting-Long-Term-Use-of-CFTR-Modulators
https://www.biospace.com/article/releases/positive-phase-3-study-results-for-trikafta-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-in-people-ages-12-and-older-with-cystic-fibrosis-who-have-one-copy-of-the-f508del-mutation-and-one-gating-or-residual-function-mutation/
https://via.tt.se/pressmeddelande/vertex-announces-expansion-of-reimbursement-agreement-with-nhs-england-to-include-kaftrio-ivacaftortezacaftorelexacaftor-in-combination-with-kalydeco-ivacaftor?publisherId=259167&releaseId=3279501#:~:text=Vertex%20Pharmaceuticals%20Incorporated%20(Nasdaq%3A%20VRTX,mg%2C%20ahead%20of%20the%20medicine's
https://www.raps.org/news-and-articles/news-articles/2020/6/ema-recommends-eight-new-medicines-refuses-one
http://www.pharmatimes.com/news/eu_expands_reach_of_vertex_cf_drug_kalydeco_1341979
https://www.raps.org/news-and-articles/news-articles/2019/11/fda-approves-5-new-costly-drugs-well-ahead-of-acti
https://www.reuters.com/article/us-britain-cystic-fibrosis-drug/vertex-deal-with-wales-expands-cystic-fibrosis-treatment-coverage-to-all-of-uk-idUSKBN1XN1IK
http://www.pharmafile.com/news/533429/vertexs-cystic-fibrosis-portfolio-be-made-available-across-northern-ireland-and-wales
http://www.pharmatimes.com/news/impressive_results_for_trikafta_in_cystic_fibrosis_1315050
https://www.fiercepharma.com/pharma/vertex-s-triple-combo-launch-trikafta-underway-as-drugmaker-humming-analyst-says
Market Place
Share 
